Showing results (151-160 of 384) with videos related to

Sort By:
Pageof 39
Rare Tumors|November 8, 2024
The efficacy of combination immunotherapy with ipilimumab plus nivolumab in metastatic myxofibrosarcomaFoteini Kalofonou, Andrea Napolitano, Charlotte Benson, et al.
Rare Tumors|September 11, 2020
Epithelioid malignant peripheral nerve sheath tumor arising in schwannomaNicholas Heatley, Eva Kolson Kokohaare, Dirk C Strauss, et al.
Rare Tumors|July 30, 2025
Epidemiology and survival outcomes for liposarcoma patients in England: An observational cohort study using real world dataJessie O Oyinlola, Mounia Beloueche-Babari, Monika Frysz, et al.
Frontiers in Oncology|March 12, 2024
The patient perspective on sirolimus for epithelioid hemangioendothelioma (EHE): results of a community survey highlighting the importance of equitable access to treatmentsDenise Robinson, Hugh Leonard, Giacomo Giulio Baldi, et al.
American Journal of Clinical Oncology|November 3, 2015
Successful Ifosfamide Rechallenge in Soft-Tissue SarcomaJonathan Noujaim, Anastasia Constantinidou, Christina Messiou, et al.
Expert Review of Anticancer Therapy|November 1, 2019
The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanibChristopher P Wilding, Mark L Elms, Ian Judson, et al.
Rare Tumors|October 18, 2016
Rare Aggressive Behavior of <i>MDM2</i>-Amplified Retroperitoneal Dedifferentiated Liposarcoma, with Brain, Lung and Subcutaneous MetastasesImen Ben Salha, Shane Zaidi, Jonathan Noujaim, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2005
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mgJohn R Zalcberg, Jaap Verweij, Paolo G Casali, et al.
Rare Tumors|August 13, 2015
Clinical Activity of Pazopanib in Metastatic Extraosseous Ewing SarcomaSteven Attia, Scott H Okuno, Steven I Robinson, et al.
European Journal of Cancer (Oxford, England : 1990)|August 1, 2006
Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG)Martine Van Glabbeke, Jaap Verweij, Paolo G Casali, et al.
Pageof 39